SML Biopharm was invited to the Riyadh Global Medical Biotechnology Summit (RGMBS) 2024, held in Riyadh, Saudi Arabia from November 10 to 12, where it shared its research achievements and innovative vision for disease treatment with investors and companies from around the world and sought to expand collaboration.
At the summit, SML Biopharm presented under the theme "mRNA-based therapeutics: Innovative strategies for treatment utilizing in vivo system."
Saudi Arabia announced its National Biotechnology Strategy in 2024, setting a goal to grow into a global bio hub by 2040. Led by Crown Prince Mohammed bin Salman, the strategy includes a concrete roadmap to establish Saudi Arabia as a leading biotechnology nation in the Middle East and North Africa (MENA) region by 2030 and to strengthen international cooperation across areas such as vaccine development and bio-manufacturing. As part of this initiative, and under the patronage of Crown Prince Mohammed, Saudi Arabia hosted this summit to provide a forum for global pharmaceutical companies like Sanofi, AstraZeneca, and Eli Lilly, as well as biotech firms and investors from various countries, to explore collaboration opportunities.
SML Biopharm presented its therapeutic research results based on its proprietary mRNA and LNP (lipid nanoparticle) platforms. In particular, the company introduced progress in personalized cancer vaccines and various therapeutic candidates using mRNA technology, emphasizing that its mRNA platform can play a significant role in effectively treating a wide range of diseases beyond existing treatment methods. SML Biopharm also met with representatives from the Saudi Ministry of Investment (MISA) and the Research, Development and Innovation Authority (RDIA) to discuss future collaboration.
SML Biopharm stated, "We are honored to have the opportunity to collaborate with several institutions in Saudi Arabia at this summit. By sharing our mRNA technology and know-how, we expect to create greater value. We will continue to expand our technological capabilities in the global market and enhance corporate value through diverse partnerships."
SML Biopharm will continue to strengthen cooperation with government agencies and pharmaceutical companies to provide solutions tailored to each country's disease needs and accelerate market entry.
SML Biopharm was founded in 2021 by Professor Nam Jae-hwan of the Catholic University. Based on differentiated mRNA technology, the company is developing mRNA vaccines and therapeutics across various fields and has affiliated companies under the Samkwang Biotree Group, including the Samkwang Medical Foundation, Samkwang LabTree, SML Meditree, and SML Zenitree.
Yakup News https://www.yakup.com/news/?mode=view&cat=12&cat2=121&cat3=0&nid=302269 Pharm News https://www.pharmnews.com/news/articleView.html?idxno=254081 The Bio https://www.thebionews.net/news/articleView.html?idxno=10581
